Must patients with advanced cancer choose between a phase I trial and hospice?

Cancer

Volumn 95, Issue 7, 2002, Pages 1601-1604

  Casarett, David J ^a,b,c   Karlawish, Jason H T ^b   Henry, Michelle I ^b   Hirschman, Karen B ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Institute on Aging   (United States)

Author keywords

Ethics; Hospice; Informed consent; Palliative care; Phase I trials; Research ethics

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER RESEARCH; HEALTH SURVEY; HUMAN; INFORMED CONSENT; LIFE EXPECTANCY; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TERMINAL CARE;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS, PHASE I; DATABASES, FACTUAL; DECISION MAKING; ELIGIBILITY DETERMINATION; ETHICS, MEDICAL; HEALTH CARE SURVEYS; HOSPICE CARE; HUMANS; INFORMED CONSENT; NEOPLASMS; PALLIATIVE CARE; PATIENT PARTICIPATION;

EID: 0036784438     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10820     Document Type: Article

References (17)

1. Anonymous. Cancer care during the last phase of life. J Clin Oncol. 1998;16:1986-1996.
2. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;2:175-181.
3. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115-122.
4. Daugherty C, Ratain MJ, Growchowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062-1072.
5. Schutta KM, Burnett CB. Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum. 2000;27:1435-1438.
6. Annas GJ. Informed consent, cancer, and truth in prognosis. N Engl J Med. 1993;330:223-225.
7. Miller M. Phase I cancer trials. A collusion of misunderstanding. Hastings Cent Rep. 2000;30:34-43.
8. Markman M. The ethical dilemma of phase I clinical trials. CA. 1986;36:367-369.
9. Sachs GA. Opportunities for promoting palliative medicine in cancer research. Cancer Invest. 1998;16:503.
10. Office of the Inspector General. Medicare hospice beneficiaries: services and eligibility (Report OEI-04-93-00270). Washington, DC: Government Printing Office, 1993.
11. National Hospice Organization: Standards and Accreditation Committee 1995-6. A pathway for patients and families facing terminal illness. Arlington, VA: National Hospice Organization, 1997.
12. 42 Code of Federal Regulations, Part 418 Medicare Hospice Regulations. 1996.
13. Itoh K, Sasaki Y, Fujii H, Wakita H, Igarashi T, Abe K. Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer. 1997;76:107-113.
14. Rodenhuis S, Van den Huevel W, Annyas A, Koops H, Sleijfer D, Mulder N. Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984;20:457-462.
15. http://cancertrials.nci.nih.gov. Accessed January 23, 2001.
16. National Hospice Organization Fact Sheet. 2000:http://www.nho.org/facts.htm.
17. Casarett D, Abrahm J. Comparison of patients referred to hospice vs. a bridge program: patient characteristics, needs for care, and survival. J Clin Oncol. 2001;19:2057-2063.